


# Advances in gene therapy for CLN2 batten disease

September 28 2023, by Kathryn Ryan



Effect of intracisternal administration of AAVrh.10hCLN2 vector on NHP safety, as scored from videotaped behavioral assessments at multiple time points. Four treated wild-type NHPs (African Green vervets; three males and one

female) were assessed for behavior parameters at 4 time points: before study (Pre), day of administration (day 0), week 4, and week 8 (before necropsy). At indicated times, NHPs were videotaped. Results of 20 behavioral parameters (see Supplementary Table S1 for parameters assessed) for each NHP in the study are shown as sums. Linked data plots over time for each NHP (means of three reviewers, *yellow*, PBS [M]; *green*, PBS [M]; *red*, AAVrh.10hCLN2 [F]; *blue*, AAVrh.10hCLN2 [M]). Note: no NHP exhibited “Unhealthy” behaviors. NHP, nonhuman primate; PBS, phosphate buffered saline. Credit: *Human Gene Therapy* (2023). DOI: 10.1089/hum.2023.067

A new study shows that delivery of gene therapy to correct the gene mutations that cause CLN2 disease, or Batten disease, directly into the cerebrospinal fluid (CSF) has potential therapeutic effects. The study, conducted in nonhuman primates, is published in the journal *Human Gene Therapy*.

CLN2 disease is a fatal, childhood autosomal recessive disorder caused by mutations in the CLN2 gene, which encodes tripeptidyl peptidase (TPP-1). In a prior study, the investigators, Ronald Crystal, MD, and Dolan Sondhi, Ph.D., from Weill Cornell Medical College, and co-authors, found that intraparenchymal administration of an adeno-associated virus (AAV) vector encoding human CLN2 slowed but did not stop [disease progression](#).

The investigators concluded that this delivery route may have been insufficient to distribute the therapy throughout the central nervous system. Whereas in that study TPP-1 activity was >2X above controls in 30% of treated brains, in the current study, with delivery directly to the CSF, TPP-1 activity was >2X above controls in 50% and 41% of the brains of the two treated animals. CSF TPP-1 levels in treated animals were 43-62% of normal human levels.

"Batten disease is a profoundly tragic disorder in which children develop normally until around age 5, but then begin experiencing seizures, blindness and progressive loss of neurologic function," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Chan Medical School. "The advancement of this potential gene therapy could provide new hope to families with affected children."

**More information:** Bishnu P. De et al, Assessment of Safety and Biodistribution of AAVrh.10hCLN2 Following Intracisternal Administration in Nonhuman Primates for the Treatment of CLN2 Batten Disease, *Human Gene Therapy* (2023). [DOI: 10.1089/hum.2023.067](https://doi.org/10.1089/hum.2023.067)

Provided by Mary Ann Liebert, Inc

Citation: Advances in gene therapy for CLN2 batten disease (2023, September 28) retrieved 29 April 2024 from <https://medicalxpress.com/news/2023-09-advances-gene-therapy-cln2-batten.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.